CN Bio Innovations Raises $9M in Funding

CN Bio Innovations, a cell culture company based in Cambridge, UK, has secured $9 million in funding led by CITIC Securities Investment Co., Ltd. The company plans to use the funds for commercial development, strengthening its position in the US, expanding operations across Europe, and driving sales of products and services, including the PhysioMimix™ platform. CN Bio's technology focuses on micro-physiological systems for drug discovery, providing predictive human tissue-based data.

CN Bio Innovations Raises $9 Million to Advance Drug Discovery Technology

CN Bio Innovations is a Cambridge, England, UK-based cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery. The company provides micro-physiological systems that enable researchers to study drug metabolism, toxicology and specific disease models on single- and multi-organ systems. CN Bio's technologies are able to replicate the micro-environments, cell-cell interactions and biological processes that occur in vivo, to bridge the gap between traditional cell culture assays and human studies, improving drug discovery while reducing research and development costs.

A cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery.

5 years ago

CN Bio Innovations Raises $9 Million to Advance Drug Discovery Technology

ProblemHealthcare

Solution

Covered on